Filing Details

Accession Number:
0001567619-19-023163
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-12-16 19:34:33
Reporting Period:
2019-12-12
Accepted Time:
2019-12-16 19:34:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1348911 Kalvista Pharmaceuticals Inc. KALV Pharmaceutical Preparations (2834) 200915291
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1691102 Christopher Yea C/O Kalvista Pharmaceuticals, Inc.
55 Cambridge Parkway, Suite 901E
Cambridge MA 02142
Chief Development Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-12-12 199 $0.00 83,168 No 4 M Direct
Common Stock Disposition 2019-12-12 199 $17.00 82,969 No 4 S Direct
Common Stock Acquisiton 2019-12-13 1,500 $0.00 84,469 No 4 M Direct
Common Stock Disposition 2019-12-13 1,500 $17.05 82,969 No 4 S Direct
Common Stock Acquisiton 2019-12-16 3,010 $0.00 85,979 No 4 M Direct
Common Stock Disposition 2019-12-16 3,010 $17.05 82,969 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2019-12-12 199 $0.00 199 $0.00
Common Stock Employee Stock Option (Right to Buy) Disposition 2019-12-13 1,500 $0.00 1,500 $0.00
Common Stock Employee Stock Option (Right to Buy) Disposition 2019-12-16 3,010 $0.00 3,010 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
94,546 2026-03-30 No 4 M Direct
93,046 2026-03-30 No 4 M Direct
90,036 2026-03-30 No 4 M Direct
Footnotes
  1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.13 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. This option is 100% vested and exercisable.
  4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.16 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.